Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of Hospice and Palliative Nursing : JHPN : the Official Journal of the Hospice and Palliative Nurses Association|March 21, 2019
Improving Attitudes and Perceptions About End-of-Life Nursing on a Hospital-Based Palliative Care UnitKristine J Harrington, Mary Lou Affronti, Susan M Schneider, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 10, 2024
MASCC 2023 Patient-Centered Antiemetic Guidelines and Education Statements: an evidence-based and consensus resource for patientsMary Lou Affronti, Jiyeon Lee, Alex Molassiotis, et al.
Clinical Journal of Oncology Nursing|July 23, 2024
The Impact of Independent Chemotherapy Prescribing by Advanced Practice Providers on Patient Safety and Clinician SatisfactionNicole LeStrange, AnnMarie Walton, Joni L Watson, et al.
Neuro-Oncology Practice|February 7, 2025
Financial toxicity of oral chemotherapy in patients with primary brain tumorsMallika P Patel, Mary Lou Affronti, Evan D Buckley, et al.
Therapeutics and Clinical Risk Management|January 19, 2017
A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumabMary Lou Affronti, Sarah Woodring, Katherine B Peters, et al.
Seminars in Oncology Nursing|November 10, 2018
Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade GliomaMary Lou Affronti, Dina Randazzo, Eric S Lipp, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 9, 2016
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ)Mary Lou Affronti, Sarah Woodring, Karen Allen, et al.
The Oncologist|April 19, 2018
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant GliomaMary Lou Affronti, Jennifer Gamboa Jackman, Frances McSherry, et al.
Cancer|June 11, 2009
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapyMary Lou Affronti, Christopher R Heery, James E Herndon, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 24, 2019
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomideMallika P Patel, Sarah Woodring, Dina M Randazzo, et al.
Pageof 3